neurotrophic factor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-01. Anything still debated is marked as such rather than presented as settled.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
| Property | Value | Notes |
|---|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Heptapeptide; ACTH(4-10) analog extended at C-terminus |
| Molecular mass | ~813.9 Da | Free peptide, unmodified |
| Appearance | White to off-white powder | Typical lyophilized solid |
| Solubility | Soluble in water and saline | Also soluble in common aqueous buffers |
| Storage (solid) | -20 °C, desiccated | Protect from moisture and repeated thawing |
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
When Winston Churchill became Prime Minister in 1940, he bypassed the War Office altogether, and appointed himself Minister of Defence (though there was, curiously, no ministry of defence until 1947). Clement Attlee continued this arrangement when he came to power in 1945, but appointed a separate Minister of Defence for the first time in 1947. In 1964, the present form of the Ministry of Defence was established, unifying the War Office, Admiralty, and Air Ministry.
1-Pyrroline-5-carboxylic acid (systematic name 3,4-dihydro-2H-pyrrole-2-carboxylic acid) is a cyclic imino acid. Its conjugate base and anion is 1-pyrroline-5-carboxylate (P5C). In solution, P5C is in spontaneous equilibrium with glutamate-5-semialdehyde (GSA).
Hydroxyl radicals are highly reactive and undergo chemical reactions that make them short-lived. When biological systems are exposed to hydroxyl radicals, they can cause damage to cells, including those in humans, where they can react with DNA, lipids, and proteins.
=== Books === Two biographies have been written about Staley, both authored by Adriana Rubio—Layne Staley: Angry Chair released in 2003, which contains an alleged final interview of Staley that Rubio claimed to have conducted less than three months before his death, and Layne Staley: Get Born Again, released in 2009, a revised and updated version of her earlier book. Staley's family has disputed Rubio's work, stating they do not believe she interviewed him in 2002. When questioned about the authenticity of the book, Rubio refused to confirm the interview was genuine. Staley's last interview was for the radio program Rockline on July 19, 1999, promoting the release of the compilation album Nothing Safe: Best of the Box with the other members of Alice in Chains. The content of Rubio's book, including what she referred to as Staley's final interview, was called into question in journalist David De Sola's 2015 book Alice in Chains: The Untold Story. De Sola questions not only the content of the interview, which portrays Staley as using his lyrics in casual conversation, it also indicates that Rubio never spoke to him, citing her refusal to release the tape with the interview and the fact that not even her publisher had access to the tape. One of Staley's sisters, Liz Coats, likewise doubted the veracity of the book. Staley was featured on the books Grunge Is Dead: The Oral History of Seattle Rock Music (2009) by Greg Prato, and Everybody Loves Our Town: An Oral History of Grunge (2011) by Mark Yarm.
Sources: en.wikipedia.org
The surgeon designs the nasolabial flap and sets its central axis at a 45-degree angle from the (long) axis of the nasal dorsum. The shape of the skin flap is cut from the wound template fabricated by the surgeon. An incision is made to the flap (without an anaesthetic injection of epinephrine), which then is elevated and oriented, in an inferior-to-superior direction, between the subcutaneous fat and the muscle fascia. The cutting continues until the skin flap can be freely transposed upon the nasal defect. A Burrow's triangle is excised from the skin between the medial border of the flap and the nasal dorsum; the triangle can be cut either before or after the elevation of the nasolabial. The flap then is bent back (reflected), and can be thinned (cut) under loupe magnification; however, a nasolabial flap cannot be thinned as easily as an axial skin-flap. After the nasolabial flap has been emplaced, the flap donor-site wound is sutured closed. For a wound of the lateral nasal wall that is less than 15 mm wide, the flap donor-site can be closed primarily, with sutures. For a wound wider than 15 mm—especially a wound that comprehends the alar lobule and the lateral wall of the nose—primary closure is not indicated, because such a wound closure imposes excessive stresses upon the skin flap, thereby risking either blanching (whitening) or distortion, or both. Such risks are avoided by advancing (moving) the skin of the cheek towards the nasofacial junction, where it is sutured to the deep tissues.
Methylene blue is a monoamine oxidase inhibitor (MAOI) and, if infused intravenously at doses exceeding 5 mg/kg, may result in serotonin syndrome if combined with any selective serotonin reuptake inhibitors (SSRIs) or other serotonergic drugs (e.g., duloxetine, sibutramine, venlafaxine, clomipramine, imipramine). It causes hemolytic anemia in carriers of the G6PD enzymatic deficiency (favism). The actual degree of this danger is a subject of controversy as the association was made based on very few cases. A 2018 meta-analysis on clinical trials against malaria in Africa, where the moderate A minus type of G6PD deficiency is prevalent, shows no association between MB and hemolysis in such patients. There was, however, a clinically insignificant reduction in hemoglobin.
Flexible linkers may consist of many small glycine residues, giving them the ability curl into a dynamic, adaptable shape. Rigid linkers may be formed of large, cyclic proline residues, which can be helpful when highly specific spacing between domains must be maintained. In vivo cleavable linkers are unique in that they are designed to allow the release of one or more fused domains under certain reaction conditions, such as a specific pH gradient, or when coming in contact with another biomolecule in the cell.
==== Environmental analysis ==== GC-EI-MS has been successfully used for the determination of pesticide residues in fresh food by a single injection analysis. In this analysis 81 multi-class pesticide residues were identified in vegetables. For this study the pesticides were extracted with dichloromethane and further analyzed using gas chromatography–tandem mass spectrometry (GC–MS–MS). The optimum ionization method can be identified as EI or chemical ionization (CI) for this single injection of the extract. This method is fast, simple and cost effective since high numbers of pesticides can be determined by GC with a single injection, considerably reducing the total time for the analysis.
Enzymatic degradation of κ-casein. Micellar flocculation. Gel formation. Each step follows a different kinetic pattern, the limiting step in milk-clotting being the degradation rate of κ-casein. The kinetic pattern of the second step of the milk-clotting process is influenced by the cooperative nature of micellar flocculation, whereas the rheological properties of the gel formed depend on the type of action of the proteases, the type of milk, and the patterns of casein proteolysis. The overall process is influenced by several different factors, such as pH or temperature. The conventional way of quantifying a given milk-clotting enzyme employs milk as the substrate and determines the time elapsed before the appearance of milk clots. However, milk clotting may take place without the participation of enzymes because of variations in physicochemical factors, such as low pH or high temperature. Consequently, this may lead to confusing and irreproducible results, particularly when the enzymes have low activity. At the same time, the classical method is not specific enough, in terms of setting the precise onset of milk gelation, such that the determination of the enzymatic units involved becomes difficult and unclear. Furthermore, although it has been reported that κ-casein hydrolysis follows typical Michaelis–Menten kinetics, it is difficult to determine with the classic milk-clotting assay.
Sources: en.wikipedia.org
== Advantages == As a separation technique, GPC has many advantages. First of all, it has a well-defined separation time due to the fact that there is a final elution volume for all unretained analytes. Additionally, GPC can provide narrow bands, although this aspect of GPC is more difficult for polymer samples that have broad ranges of molecular weights present. Finally, since the analytes do not interact chemically or physically with the column, there is a lower chance for analyte loss to occur. For investigating the properties of polymer samples in particular, GPC can be very advantageous. GPC provides a more convenient method of determining the molecular weights of polymers. In fact most samples can be thoroughly analyzed in an hour or less. Other methods used in the past were fractional extraction and fractional precipitation. As these processes were quite labor-intensive molecular weights and mass distributions typically were not analyzed. Therefore, GPC has allowed for the quick and relatively easy estimation of molecular weights and distribution for polymer samples
== External links == Cooking For Engineers: Smoke Point of Various Fats - another list of smoke points along with some discussion on the subject Good Eats: Cooking Oil Smoke Points Archived 2016-03-03 at the Wayback Machine The Culinary Institute of America (1996). The New Professional Chef (6th ed.). John Wiley & Sons.
=== Risk factor mitigation === Most patients with calciphylaxis are already on hemodialysis, or simply dialysis, but the length or frequency of sessions may be increased. The majority of dialysis patients are on a 4-hour three times per week schedule. Indications for increasing dialysis session length or frequency include electrolyte and mineral abnormalities, such as hyperphosphatemia, hypercalcemia, and hyperparathyroidism, all of which are also risk factors for development of calciphylaxis. Peritoneal dialysis patients should also transition to hemodialysis, as only hemodialysis carries the added benefit of better phosphate and calcium control. Surgical parathyroidectomy is also recommended for those who have difficulty managing phosphate and calcium level balance. However, risks include development of post-operative hungry bone syndrome (HBS), a disease state that causes low calcium and requires use of calcium supplementation and calcitriol, which should be avoided in patients with end-stage kidney disease and calciphylaxis.
== Plastics == Plastic drawing, sometimes referred to as cold drawing, is the same process as used on metal bars, applied to plastics. Plastic drawing is primarily used in manufacturing plastic fibers. The process was discovered by Julian W. Hill in 1930 while trying to make fibers from an early polyester. It is performed after the material has been "spun" into filaments; by extruding the polymer melt through pores of a spinneret. During this process, the individual polymer chains tend to somewhat align because of viscous flow. These filaments still have an amorphous structure, so they are drawn to align the fibers further, thus increasing crystallinity, tensile strength, and stiffness. This is done on a draw twister machine. For nylon, the fiber is stretched to four times its spun length. The crystals formed during drawing are held together by hydrogen bonds between the amide hydrogens of one chain and the carbonyl oxygens of another chain. Polyethylene terephthalate (PET) sheet is drawn in two dimensions to make BoPET (biaxially-oriented polyethylene terephthalate) with improved mechanical properties.
Sources: en.wikipedia.org
Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.
Its sequence corresponds to the 4-10 region of corticotropin extended by three residues. This fragment lacks the region responsible for adrenal steroid release, so it is explored for neural rather than hormonal effects. The relationship explains the compound's classification among ACTH-derived peptides.
It holds approval in Russia for several neurological indications as a nasal spray or drop formulation. Regulatory agencies in the United States and the European Union have not approved it. Products sold elsewhere are generally labeled for research use only.
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.